Favipiravir (Synonyms: T-705)

Name: Favipiravir
Brand: MedChemExpress
SKU: HY-14768
Rating: 5.0 (50 reviews)

Cat. No.: HY-14768 Purity: 99.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC₅₀ of 341 nM.

For research use only. We do not sell to patients.

CAS No. : 259793-96-9

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 50 publication(s) in Google Scholar

Other Forms of Favipiravir:

50 Publications Citing Use of MCE Favipiravir

Microbiological Assay

Others

Cell Proliferation/Viability Assay

: Favipiravir purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2025 Dec;14(1):2564308. [Abstract]; Drug susceptibility profiles of Favipiravir were assessed using a viral yield reduction assay in MDCK cells. Cells were infected with IDV and IAV (MOI = 0.1), followed by removal of the virus inoculum and treatment with the drugs. Supernatants from IDV and Influenza A virus (IAV) infections were collected at 72 and 48 hpi, respectively, and viral titres were determined in MDCK cells. Antiviral activity (%) was calculated relative to virus-free and drug-free controls.

: Favipiravir purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]; Vero E6 cells in 12-well plates were infected with HTNV at an FFU of 30/well (T-705; Favipiravir) and incubated with a CMC overlay supplemented with serial two-fold dilutions of inhibitors. At 5 dpi, the foci were counted and calculated. These experiments were performed independently at least three times with similar results.

: Favipiravir purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]; Inhibitory effects of T-705 (Favipiravir) and BXA (Baloxavir) on HTNV replication, as measured by FFA. Vero E6 cells were infected with HTNV at an FFU of 30/well (T-705) or 50/well (BXA) and treated with serial two-fold dilutions of inhibitors. The foci were counted 5 dpi. Each point represents the mean and SD of three independent experiments.

: Favipiravir purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]; Cell viability as a percentage of the control cell (treated with DMSO for T-705 or PBS for BXA) viability in uninfected Vero E6 cells incubated for 72 h post-T-705 (Favipiravir)/BXA (Baloxavir) treatment. Each point represents the mean and SD of three independent experiments.

: Favipiravir purchased from MedChemExpress. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316. [Abstract]; Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. Viral replications in cells were detected by IFA and the mean fluorescence percentages (a, c, e, g) were calculated

: Favipiravir purchased from MedChemExpress. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316. [Abstract]; Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. The virus titers in supernatant (b, d, f, h) were determined and compared with the viral titers in mock group. All e

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

RNA Polymerase

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	CC₅₀	> 100 μM Compound: 6; T-705	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	CC₅₀	> 50 μM Compound: FPV	Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay	[PMID: 39153334]
HEK-293T	EC₅₀	8.29 μM Compound: 6; T-705	Anti-influenza activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	EC₅₀	> 10 μM Compound: 6; T-705	Anti-influenza activity against Influenza A virus H3N2 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza A virus H3N2 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	EC₅₀	> 10 μM Compound: 6; T-705	Anti-influenza activity against Influenza B virus Victoria/2/87 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza B virus Victoria/2/87 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
HEK-293T	EC₅₀	> 10 μM Compound: 6; T-705	Anti-influenza activity against Influenza B virus Yamagata/16/88 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay Anti-influenza activity against Influenza B virus Yamagata/16/88 infected in HEK293T cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by CCK-8 assay	[PMID: 38775356]
MDCK	CC₅₀	> 100 μM Compound: T-705	Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis	[PMID: 23419738]
MDCK	CC₅₀	> 100 μM Compound: T-705	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36764470]
MDCK	CC₅₀	> 1000 μM Compound: Favipiravir	Cytotoxicity against MDCK cells assessed as reduction in cell viability Cytotoxicity against MDCK cells assessed as reduction in cell viability	[PMID: 38283223]
MDCK	CC₅₀	> 1000 μM Compound: T-705	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability Cytotoxicity against dog MDCK cells assessed as reduction in cell viability	[PMID: 35729787]
MDCK	CC₅₀	> 2000 μg/mL Compound: Favipiravir	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 35196598]
MDCK	CC₅₀	> 250 μM Compound: FPV	Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay	[PMID: 39153334]
MDCK	CC₅₀	> 250 μM Compound: T-705	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
MDCK	CC₅₀	> 250 μM Compound: T-705	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
MDCK	CC₅₀	> 400 μM Compound: 1; T-705	Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay Cytotoxicity against MDCK cells after 10 mins by CellTiter-Glo assay	[PMID: 27120583]
MDCK	CC₅₀	> 641 μM Compound: T-705	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 17194832]
MDCK	EC₅₀	0.19 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.38 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.45 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.57 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.83 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.83 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.83 μM Compound: T-705	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.89 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.89 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	0.96 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.21 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.21 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.21 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.27 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.32 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	1.341 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.4 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.4 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.46 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.53 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.59 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.59 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.72 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.85 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	1.93 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	1.94 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	1.97 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	10.2 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	11.5 μM Compound: T-705	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	12.1 μM Compound: T-705	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	2.23 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	2.48 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	2.55 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	2.6 μM Compound: T-705	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	2.7 μM Compound: 1; T-705	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by viral infection measured after 20 hrs by fluorescence assay Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by viral infection measured after 20 hrs by fluorescence assay	[PMID: 27120583]
MDCK	EC₅₀	2.84 μM Compound: T-705	Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	2.87 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	2.93 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	2.93 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	22.48 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	3 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	3.25 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	3.38 μM Compound: T-705	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	3.63 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	3.95 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.01 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.08 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.14 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.2 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.46 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.5 μM Compound: T-705	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	4.52 μM Compound: T-705	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.7 μM Compound: T-705	Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	4.71 μM Compound: T-705	Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
MDCK	EC₅₀	4.9 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.03 μM Compound: T-705	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.03 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.22 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.22 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.3 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.41 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	5.99 μM Compound: T-705	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	6.62 μM Compound: T-705	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	6.95 μM Compound: T-705	Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis	[PMID: 23419738]
Vero	CC₅₀	1114 μM Compound: T-705	Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay	[PMID: 17606691]
Vero	CC₅₀	> 1000 μM Compound: 12	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 7 days by resazurin staining based analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 7 days by resazurin staining based analysis	[PMID: 38128296]
Vero	CC₅₀	> 1000 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 33766766]
Vero	CC₅₀	> 1000 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero cells infected with Marburgvirus Angola Cytotoxicity against African green monkey Vero cells infected with Marburgvirus Angola	[PMID: 36898483]
Vero	CC₅₀	> 1000 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero cells infected with Zaire ebolavirus Cytotoxicity against African green monkey Vero cells infected with Zaire ebolavirus	[PMID: 36898483]
Vero	CC₅₀	> 6257 μM Compound: T-705	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 3 to 5 days Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 3 to 5 days	[PMID: 17606691]
Vero	CC₅₀	> 6370 μM Compound: T-705	Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay	[PMID: 18955536]
Vero	EC₅₀	18.6 μg/mL Compound: Favipiravir	Antiviral activity against Ebolavirus infected in African green monkey Vero cells by immunofluorescent assay Antiviral activity against Ebolavirus infected in African green monkey Vero cells by immunofluorescent assay	[PMID: 31431358]
Vero	EC₅₀	180 μM Compound: T-705	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis	[PMID: 18955536]
Vero	EC₅₀	270 μM Compound: T-705	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay	[PMID: 18955536]
Vero	EC₅₀	270 μM Compound: T-705	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay	[PMID: 18955536]
Vero	EC₅₀	3.5 μg/mL Compound: 55	Antiviral activity against Zika virus MR766 infected in Vero cells assessed as reduction in viral replication by plaque reduction assay Antiviral activity against Zika virus MR766 infected in Vero cells assessed as reduction in viral replication by plaque reduction assay	[PMID: 33486200]
Vero	EC₅₀	5 μM Compound: T-705	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	EC₅₀	6 μM Compound: T-705	Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	EC₅₀	6 μM Compound: T-705	Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero C1008	CC₅₀	5.262 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability	[PMID: 36708678]
Vero C1008	CC₅₀	5262 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability	[PMID: 37329713]
Vero C1008	CC₅₀	> 1000 μM Compound: Favipiravir	Cytotoxicity against african green monkey Vero E6 cells Cytotoxicity against african green monkey Vero E6 cells	[PMID: 39248591]
Vero C1008	CC₅₀	> 400 μM Compound: 4; FPV	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	[PMID: 32845145]
Vero C1008	CC₅₀	> 400 μM Compound: 55	Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay	[PMID: 33486200]
Vero C1008	CC₅₀	> 400 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay	[PMID: 32511912]
Vero C1008	CC₅₀	> 400 μM Compound: Favipiravir	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	CC₅₀	> 400 μM Compound: Favipiravir	Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth by CCK-8 assay	[PMID: 36965227]
Vero C1008	CC₅₀	> 400 μM Compound: T-705	Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition incubated for 48 hrs by CCK8 assay	[PMID: 32771797]
Vero C1008	EC₅₀	10.5 μg/mL Compound: 55	Antiviral activity against Ebolavirus infected in Vero E6 cells assessed as reduction in viral replication measured after 5 days by immunofocus assay Antiviral activity against Ebolavirus infected in Vero E6 cells assessed as reduction in viral replication measured after 5 days by immunofocus assay	[PMID: 33486200]
Vero C1008	EC₅₀	61.88 μM Compound: 55	Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	IC₅₀	67 μM Compound: 22	Antiviral activity against EBOV infected in Vero E6 cells assessed as reduction in virus titer incubated for 5 days by immunofocus assay Antiviral activity against EBOV infected in Vero E6 cells assessed as reduction in virus titer incubated for 5 days by immunofocus assay	[PMID: 33352046]

In Vitro

Favipiravir (T 705) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir (T 705) is a novel antiviral compound that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. Favipiravir-RTP does not inhibit the human DNA polymerase α, β or γ with IC₅₀>1 mM. The IC₅₀ for the human RNA polymerase II is 905 μM; Favipiravir is therefore 2,650 times more selective for the influenza virus RdRP, consistent with the lack of inhibition of host-cell DNA and RNA synthesis^[1]. Favipiravir (T 705) acts as a pro-drug, its cytotoxicity is expected to be cell-line dependent. Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC₅₀: 250±11 μM) and MNV RNA synthesis in cell culture (EC₅₀:124±42 μM). Despite this rather modest antiviral activity, Favipiravir (T 705) is able to completely inhibit norovirus replication at a concentration of 100 μg/mL, which is a concentration that has little or no adverse effect on the host cell (cell viability >80%)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. Favipiravir (T 705) also provides significant protection against the A/Duck/MN/1525/81(H5N1) virus at a dose of 33 mg/kg/day or more, regardless of the number of daily doses. When given 4 times a day, all mice survive^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

157.10

Formula

C₅H₄FN₃O₂

CAS No.

259793-96-9

Appearance

Solid

Color

White to light yellow

SMILES

O=C(N)C1=NC(F)=CNC1=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (636.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 6.25 mg/mL (39.78 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.3654 mL	31.8269 mL	63.6537 mL
5 mM	1.2731 mL	6.3654 mL	12.7307 mL
10 mM	0.6365 mL	3.1827 mL	6.3654 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution
Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 4.55 mg/mL (28.96 mM); Clear solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (63.65 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (248 KB) RP-HPLC (256 KB)

Handling Instructions (2659 KB)

References

[1]. Furuta Y, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54. [Content Brief]

[2]. Rocha-Pereira J, et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80. [Content Brief]

Cell Assay ^[2]	The antiviral activity of Favipiravir (T 705) is determined using an MTS-based CPE reduction assay in the MNV/RAW 264.7 cell line. To this end, RAW 264.7 cells are seeded (1×10⁴ cells/well) in 96-well plates and infected with MNV at an MOI of 0,001 in the presence (or absence) of a dilution series of Favipiravir (T 705) (3.13-200 μg/mL). Following 3 days of incubation, i.e. until complete CPE is observed in infected untreated cells, cell culture supernatants are collected for quantification of viral RNA load by quantitative RT-PCR (qRT-PCR). For the MTS reduction assay an MTS/Phenazine methosulphate (PMS) stock solution (2 mg/mL MTS and 46 g/mL PMS in PBS at pH 6-6.5) is diluted 1/20 in MEM. To each well, 75 μL of MTS/PMS solution is added and the optical density (OD) is read at 498 nm 2 h later. The % CPE reduction is calculated as [(OD_treated)_MNW−OD_VC]/[OD_CC-OD_VC]×100, where OD_CC represents the OD of the uninfected untreated cells, whereas OD_VC and (OD_treated)_CC represent the OD of infected untreated cells and virus-infected cells treated with a compound concentration, respectively. The EC₅₀ is defined as the compound concentration that protected 50% of cells from virus-induced CPE. Adverse effects of the molecule on the host cell are also assessed by means of the MTS-method, by exposing uninfected cells to the same concentrations of Favipiravir for 3 days. The % cell viability is calculated as (OD_treated/OD_CC)×100, where OD_CC is the OD of uninfected untreated cells and OD_treated are uninfected cells treated with compound. The CC₅₀ is defined as the compound concentration that reduces the number of viable cells by 50%. The selectivity index (SI) is calculated as CC₅₀/EC₅₀^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] Favipiravir (T 705) has also been shown to protect mice against lethal infection by a variety of influenza virus strains. When Favipiravir is orally administered 2 or 4 times a day for 5 days in mice infected with lethal doses of influenza virus A/Victoria/3/75(H3N2), A/Osaka/5/70(H3N2) or A/Duck/MN/1525/81(H5N1). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Furuta Y, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446-54. [Content Brief] [2]. Rocha-Pereira J, et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	6.3654 mL	31.8269 mL	63.6537 mL	159.1343 mL
	5 mM	1.2731 mL	6.3654 mL	12.7307 mL	31.8269 mL
	10 mM	0.6365 mL	3.1827 mL	6.3654 mL	15.9134 mL
	15 mM	0.4244 mL	2.1218 mL	4.2436 mL	10.6090 mL
	20 mM	0.3183 mL	1.5913 mL	3.1827 mL	7.9567 mL
	25 mM	0.2546 mL	1.2731 mL	2.5461 mL	6.3654 mL
	30 mM	0.2122 mL	1.0609 mL	2.1218 mL	5.3045 mL
DMSO	40 mM	0.1591 mL	0.7957 mL	1.5913 mL	3.9784 mL
	50 mM	0.1273 mL	0.6365 mL	1.2731 mL	3.1827 mL
	60 mM	0.1061 mL	0.5304 mL	1.0609 mL	2.6522 mL
	80 mM	0.0796 mL	0.3978 mL	0.7957 mL	1.9892 mL
	100 mM	0.0637 mL	0.3183 mL	0.6365 mL	1.5913 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Favipiravir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Favipiravir259793-96-9T-705T705T 705DNA/RNA SynthesisInfluenza VirusSARS-CoVBacterialSARS coronavirusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Favipiravir (Synonyms: T-705)

Customer Review

Other Forms of Favipiravir:

Favipiravir Related Antibodies

50 Publications Citing Use of MCE Favipiravir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Favipiravir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Favipiravir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report